An expert explained the importance of the FDA’s approval of Ensacove for patients with ALK-positive non-small cell lung cancer. Ensacove (ensartinib) has been approved by the Food and Drug ...

Roche's Alecensa has been recommended for routine NHS use as an adjuvant treatment for ALK-positive non-small cell lung cancer (NSCLC), the first targeted therapy for this indication. Alecensa ...

An application was submitted to the European Medicines Agency seeking approval for treatment with sugemalimab in stage 3 ...

A genetic mutation in the lungs can cause non-small cell lung cancer (NSCLC ... and lorlatinib (Lorbrena) to treat ALK-positive lung cancer. However, a doctor may still prescribe if you have ...

The FDA has approved ensartinib in adult patients with anaplastic lymphoma kinase (ALK)–positive locally advanced or metastatic non–small cell lung cancer (NSCLC) naive to ALK treatment.

If your non-small cell lung cancer (NSCLC) involves a gene mutation ... If your test results come back positive for a gene mutation, your doctor can give you medications that specifically target ...

EGFR-positive lung cancer Anaplastic lymphoma kinase (ALK) positive lung cancer (ROS1)-positive NSCLC According to research, about 50% to 60% of people with EGFR- or ALK-positive lung cancer go on ...

SUZHOU, China I March 23, 2025 I CStone Pharmaceuticals ("CStone", HKEX: 2616), a biopharmaceutical company dedicated to developing innovative cancer ...